Hospital Clínic, Barcelona, Spain.
Hospital Universitari de Bellvitge, l'Hospitalet del Llobregat, Barcelona, Spain.
Mod Pathol. 2019 May;32(5):621-626. doi: 10.1038/s41379-018-0188-2. Epub 2018 Dec 14.
The involvement of human papillomavirus (HPV) in laryngeal and hypopharyngeal lymphoepithelial carcinoma was investigated in a series of ten cases (seven laryngeal and three hypopharyngeal), retrieved from the files of three tertiary hospitals in the 2000-2017 period, through polymerase chain reaction with SPF10 primers and INNO-LiPA HPV Genotyping Extra II (Innogenetics). Epstein-Barr virus (EBV) was tested in all cases with in situ hybridization INFORM EBER Probe (Ventana Medical Systems). p16 and p53 expression were immunohistochemically analyzed. Calculated annual incidence was 0.013/100,000, and prevalence was 0.2% of laryngeal and hypopharyngeal carcinomas. All cases were EBV negative. HPV was detected in five cases, three of which also overexpressed p16. HPV16 was detected in four cases, and HPV58 in one case. Five cases were HPV negative, only one of these five overexpressed p16. No recurrence was observed in nine cases during follow-up. The 5-year disease-specific-survival rate was 100%. Mean overall survival was 87 months. Lymphoepithelial carcinoma of the larynx and hypopharynx are not related to EBV. Simultaneous HPV+/p16+ is consistent with HPV causation in a fraction of laryngeal and hypopharyngeal lymphoepithelial carcinomas.
研究了十例（7 例喉部和 3 例下咽）喉和下咽淋巴上皮癌中人类乳头瘤病毒（HPV）的参与情况，这些病例是从 2000-2017 年期间的三家三级医院的档案中检索出来的，通过聚合酶链反应与 SPF10 引物和 INNO-LiPA HPV Genotyping Extra II（Innogenetics）进行。所有病例均通过原位杂交 INFORM EBER Probe（Ventana Medical Systems）检测 Epstein-Barr 病毒（EBV）。p16 和 p53 的表达通过免疫组织化学进行分析。计算的年发病率为 0.013/100,000，喉和下咽癌的患病率为 0.2%。所有病例 EBV 均为阴性。在五例中检测到 HPV，其中三例也过表达 p16。在四例中检测到 HPV16，一例检测到 HPV58。五例 HPV 为阴性，其中只有一例过表达 p16。在随访期间，九例中未观察到复发。5 年疾病特异性生存率为 100%。总生存率的平均值为 87 个月。喉和下咽的淋巴上皮癌与 EBV 无关。HPV+/p16+的同时存在与部分喉和下咽淋巴上皮癌的 HPV 病因一致。
